3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

InvestorPlace05-02

Here are some of the most exciting gene editing stocks to jump into. Intellia Therapeutics (NTLA): It expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432627696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-02 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432627696","market":"us","top_or_hot":-1,"title":"3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire","media":"InvestorPlace","content":"<div>\n<p>Here are some of the most exciting gene editing stocks to jump into.\nIntellia Therapeutics (NTLA): It expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE...</p>\n\n<a href=\"https://investorplace.com/2024/05/3-gene-editing-stocks-with-the-potential-to-make-you-an-overnight-millionaire/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 18:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/05/3-gene-editing-stocks-with-the-potential-to-make-you-an-overnight-millionaire/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are some of the most exciting gene editing stocks to jump into.\nIntellia Therapeutics (NTLA): It expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE...</p>\n\n<a href=\"https://investorplace.com/2024/05/3-gene-editing-stocks-with-the-potential-to-make-you-an-overnight-millionaire/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://investorplace.com/2024/05/3-gene-editing-stocks-with-the-potential-to-make-you-an-overnight-millionaire/","article_id":"2432627696","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432627696","pubTimestamp":1714644240,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Here are some of the most exciting gene editing stocks to jump into.Intellia Therapeutics : It expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema  in the back half of 2024.Metagenomi : The company uses an AI-powered discovery engine to “find naturally occurring gene editing systems in metagenomic data.”Global X Genomics & Biotechnology ETF : Or, if you want to diversify with most gene-editing stocks at a low cost, there’s theGlobal X Genomics & Biotechnology ETF.It also expects toinitiate thePhase 3 study of NTLA-2002for the treatment of hereditary angioedema , a rare genetic condition that can lead to life-threatening swelling attacks inthe second half of the year. Should the company see solid success with NTLA-2002, it could help treatHAE right away.It’s also on trackto dose the first patient in thePhase 1 study of NTLA-3001. This is anin vivogene insertion candidate for the treatment","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4588":"碎股","FDN":"First Trust Dow Jones Internet I","BK4198":"医疗保健用品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CRSP":"CRISPR Therapeutics AG","PSQ":"纳指反向ETF","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","HAE":"美国血液技术","QQQ":"纳指100ETF","QLD":"纳指两倍做多ETF","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TQQQ":"纳指三倍做多ETF","ILMN":"Illumina","BK4548":"巴美列捷福持仓","TXG":"10x Genomics, Inc.","NTLA":"Intellia Therapeutics Inc",".IXIC":"NASDAQ Composite","MGX":"Metagenomi Technologies, LLC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","SQQQ":"纳指三倍做空ETF","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4556":"基因编辑","BK4139":"生物科技","GNOM":"Global X Genomics & Biotechnology ETF","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务","QID":"纳指两倍做空ETF"},"translate_title":"有可能让你一夜暴富的3只基因编辑股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1,"TXG":1,"NTLA":1,"MGX":1,"ILMN":1,"GNOM":1,"CRSP":1,"FDN":0.9,".IXIC":0.9,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Here are some of the most exciting gene editing stocks to jump into.\nIntellia Therapeutics (NTLA): It expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) in the back half of 2024.\nMetagenomi (MGX): The company uses an AI-powered discovery engine to “find naturally occurring gene editing systems in metagenomic data.”\nGlobal X Genomics & Biotechnology ETF (GNOM): Or, if you want to diversify with most gene-editing stocks at a low cost, there’s the Global X Genomics & Biotechnology ETF.\n\n\n\n\n\n \n\nSource: Natali_ Mis/ShutterStock.com\n\n\n\nPay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body, edit them and reintroduce them back into the body. All in an effort to help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis and even muscular dystrophy.\nMonths ago, CRISPR Therapeutics (NASDAQ:CRSP) received Food & Drug Administration approval for its sickle-cell treatment. It also received clearance for its gene-edited therapy for transfusion-dependent beta-thalassemia (TDT).\nEven more exciting, generative artificial intelligence (AI) has made its way into gene editing. Profluent, an AI-first protein design company, just introduced OpenCRISPR, an AI-generated gene editor. \n“Our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease. To spur innovation and democratization in gene editing, with the goal of pulling this future forward, we are open-sourcing the products of this initiative,” said Ali Madani, Profluent co-founder and CEO, as quoted by Fierce Biotech.\nBut that’s just the start. At the moment, there are about 7,000 diseases caused by genetic disorders, which occur when a mutation affects your genes. Or, when you have the wrong amount of genetic material, as noted by the Cleveland Clinic. Many could potentially be fixed is the hope. \nThat being said, investors may want to jump into gene editing stocks.\nIntellia Therapeutics (NTLA)\nSource: vxhal/ShutterStock.comBeaten-down shares of Intellia Therapeutics (NASDAQ:NTLA) have been on the mend after dropping from about $35 to a recent low of $19.37. Now at $21.40, I’d like to see it climb back to $26. For one, it’s nearing the presentation of Phase 1 of its ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31.\nIt also expects to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE), a rare genetic condition that can lead to life-threatening swelling attacks in the second half of the year. Should the company see solid success with NTLA-2002, it could help treatHAE right away.\nIt’s also on track to dose the first patient in the Phase 1 study of NTLA-3001. This is an in vivo gene insertion candidate for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease, as noted in a company press release.\nMetagenomi (MGX)\nSource: ShutterstockThere’s also Metagenomi (NASDAQ:MGX), which went public in February. While its chart is nothing to write home about, its artificial intelligence story is.\nAt the moment, the company uses an AI-powered discovery engine to “find naturally occurring gene editing systems in metagenomic data. Metagenomi is leveraging AI to enhance the power of CRISPR gene editing technology, as it works towards its vision of advancing therapies and cures for oncology and genetic diseases,” as noted on LinkedIn.com.\nAt just $7 a share at the moment, analysts at Jefferies say it’s a buy, with a $23 price target. The firm highlighted MGX’s next-generation editing tools. BMO Capital analysts have an outperform rating on the stock, with a $22 price target. They also noted that the company could “potentially perform all known gene editing approaches,” as quoted by Seeking Alpha. \nEven better, according to the company, “Throughout 2023, we achieved key therapeutic milestones, including preclinical proof of concept in nonhuman primates for our lead program in Hemophilia A,” said CEO Brian C. Thomas. “Looking ahead, we are planning for additional nonhuman primate data readouts over the course of this year, including 12-month data for our Hemophilia A program, expected in the second half of 2024.” \nGlobal X Genomics & Biotechnology ETF (GNOM)\nSource: Gorodenkoff / Shutterstock.comOr, if you want to diversify with most gene-editing stocks at a low cost, there’s the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM).\nWith an expense ratio of 0.50%, the exchange-traded fund (ETF) holds 41 stocks that could benefit from gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology, as noted by GlobalXETFs.com. Among its current top holdings include CRISPR Therapeutics, Illumina (NASDAQ:ILMN) and 10X Genomics (NASDAQ:TXG) to name a few.\nAt the moment, the GNOM ETF is also technically oversold around $9.84. It’s also now sitting at double-bottom support dating back to late 2023. It’s even over-extended on RSI, MACD, and Williams’ %R. From its last traded price of $9.84, I’d like to see it rally back to about $12.50.\nEven better, I can diversify with the GNOM ETF at a low cost. If I were to buy 100 shares, it would cost me $984 for exposure to its 41 holdings. If I were to buy just one of its holdings — let’s say 100 shares of CRSP — it would cost me close to $5,300.\nOn the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nIan Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.Biotech, HealthcareGrowth Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/05/3-gene-editing-stocks-with-the-potential-to-make-you-an-overnight-millionaire/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432627696"}